Tijuana decision guide
A calm, practical way to ask what is known, what needs confirmation, and what should never be assumed when considering ibogaine treatment in Tijuana.
This page supports careful verification. It does not endorse treatment, a provider, or a particular decision.
Start with uncertainty
Ibogaine is often discussed in the context of substance use, but it can involve serious medical and psychiatric questions. The medical literature on ibogaine-related cardiac risk describes concerns that should not be treated as background details.
Use the questions below to slow the process down. A program’s answer, a website claim, or a personal recommendation is not the same as independently confirming whether an arrangement is appropriate for one person’s health, medicines, history, travel circumstances, and support after return.
Before any commitment
A useful conversation makes room for details, uncertainty, and a decision not to proceed. It should not depend on urgency, vague assurances, or a promise that everyone will qualify.
Ask what information is reviewed before travel, who reviews it, what could lead to postponement or refusal, and whether answers will be provided in writing. A responsible process should be able to explain the difference between an intake conversation and a medical determination.
It is also reasonable to request a clear description of what is monitored, when monitoring happens, how medication questions are handled, and what emergency plan is in place. The FDA warning about serious ibogaine risks is a reminder that a reassuring tone does not remove the need for specific safety questions.
What to verify
Consider keeping notes of each response, what document supports it, and what remains unknown. This helps families and prospective participants compare information without relying only on memory or pressure.
A steadier lens
“If an answer matters to safety, ask what supports it—and what remains uncertain.”
Cardiac and psychiatric screening are not administrative boxes. They are central questions for any person considering ibogaine, particularly where medical history, current medicines, withdrawal, or mental health symptoms may complicate risk. The screening questions to raise before travel can help structure that conversation.
It can also help to understand that ibogaine’s history and use do not establish that it is safe or suitable for a particular person. Evidence, legal context, health status, and the quality of communication all need separate attention.
Common questions
Ask for written answers about screening, medical oversight, emergency procedures, medication review, the treatment setting, and what happens if a person is not cleared to proceed. If an answer cannot be made clear, treat that uncertainty as relevant information.
No. A careful conversation should distinguish claims from evidence and avoid guarantees about recovery, safety, or suitability. For a broader framework for evaluating options, the ibogaine relapse resource can be one starting point for organizing questions rather than assuming an outcome.
Travel does not replace ongoing support. Before committing, clarify the return-home plan, continuity of care, and how legal or medical questions will be handled. The aftercare and legal considerations page outlines reasons to address those practical details early.
Take your time
Return to the questions, compare what is documented, and bring unresolved medical or mental-health concerns to an appropriate qualified professional. You can also revisit the broader Tijuana decision guidance when you need a simpler place to begin.